{"commentary":{"count":43,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":29,"youtube":10,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05043090\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SAMETA","nct_id":"NCT05043090","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sameta-nct05043090. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SAMETA","arms":[{"description":"savolitinib 600mg plus durvalumab 1500mg","label":"Arm A","type":"EXPERIMENTAL"},{"description":"sunitinib 50mg","label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":"durvalumab 1500mg","label":"Arm C","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-02-01","type":"ESTIMATED"},"conditions":["Papillary Renal Cell Carcinoma"],"enrollment":{"count":148,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"savolitinib","type":"DRUG"},{"name":"durvalumab","type":"DRUG"},{"name":"sunitinib","type":"DRUG"}],"last_update":"2026-05-22","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib","timeFrame":"Approximately 28 months post first subject randomized"}],"references":[{"citation":"Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite FC, Ralph C, Srinivasan G, Mendez-Vidal MJ, Childress M, Li W, Boyle P, Gasco A, Markovets A, Hartmaier R, Ackerman C, Szabados BE, Priyadarshini G, Jamal F, Powles T, Suarez C. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. J Clin Oncol. 2026 Apr 20;44(12):1076-1082. doi: 10.1200/JCO-25-01840. Epub 2026 Mar 20.","pmid":"41861260","type":"DERIVED"}],"start_date":{"date":"2021-10-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","url":"https://clinicaltrials.gov/study/NCT05043090"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sameta-nct05043090"}